Mesalazine rectal gel - Gentium

Drug Profile

Mesalazine rectal gel - Gentium

Alternative Names: 5-Aminosalicylic acid rectal gel - Axcan Pharma; 5-ASA rectal gel - Axcan Pharma; Canasa Rectal Gel; Mesalamine rectal gel; Salofalk Rectal Gel

Latest Information Update: 04 Feb 2014

Price : $50

At a glance

  • Originator Gentium
  • Class Aminosalicylic acids; Anti-inflammatories; Irritable bowel syndrome therapies; Small molecules
  • Mechanism of Action Lipoxygenase-cyclooxygenase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Ulcerative colitis

Most Recent Events

  • 15 Mar 2016 Biomarkers information updated
  • 03 Feb 2014 Aptalis has been acquired by Forest Laboratories
  • 25 Feb 2008 Axcan Pharma has been acquired by Texas Pacific Group
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top